Pathology & Genetic Subtypes

When you receive an AML diagnosis, your medical team creates a highly detailed “genetic fingerprint” of your leukemia. This is because Acute Myeloid Leukemia is not a single disease; it is a highly heterogeneous group of disorders, meaning that no two patients have the exact same version of it ^[1][2]. Your treatment plan, including the choice of specific drugs and the potential need for a stem cell transplant, depends almost entirely on this unique profile ^[3][4].

The Four Pillars of Your Pathology Report

A comprehensive pathology report should be “integrated,” meaning it combines findings from four different types of specialized testing ^[5][3]:

1. Morphology (The Look): A pathologist looks at your bone marrow under a microscope to confirm that at least 20% of the cells are “blasts” (immature leukemia cells) and to see if they have any unique physical features ^[6][7].
2. Flow Cytometry (The Surface): This test identifies the “ID tags” or surface markers (such as CD33 or CD34) on the leukemia cells ^[8][9]. This acts as a baseline “fingerprint” that doctors can use later to see if any trace of the cancer remains after treatment ^[10].
3. Cytogenetics/Karyotyping (The Blueprint): This test looks at the structure of your chromosomes. Doctors look for “translocations” (where pieces of two chromosomes switch places) or missing/extra chromosomes ^[5][4].
4. Molecular Testing/NGS (The Code): Using Next-Generation Sequencing (NGS), doctors scan your DNA for tiny spelling errors called mutations ^[11][12]. This is the most detailed level of testing and often finds the specific “drivers” of your cancer.

Five Key Driver Mutations

Your report will likely mention several genes. Five of the most critical ones in AML include:

• FLT3: This is one of the most common mutations. It acts like a “stuck accelerator,” telling the cancer cells to grow and divide ^[13][14]. There are two main types of FLT3 mutations: ITD (Internal Tandem Duplication) and TKD (Tyrosine Kinase Domain), which can affect your risk level differently ^[13]. If you have a FLT3 mutation, your doctor may add a FLT3 inhibitor (a targeted drug) to your chemotherapy ^[15][16].
• NPM1: This is often considered a “favorable” mutation when it occurs without certain other high-risk changes ^[13][17]. It generally responds well to intensive chemotherapy ^[4].
• CEBPA: When this mutation occurs in a specific way (called “biallelic” or “bZIP” mutations), it is typically associated with a very good response to treatment ^[16][14].
• IDH1 & IDH2: These mutations produce a substance that blocks cells from maturing ^[18]. Like FLT3, there are now specific targeted drugs (IDH inhibitors) that can target these mutations directly ^[15][17].
• TP53: This mutation is associated with “adverse” risk because it can make the leukemia more resistant to standard intensive chemotherapy ^[19][20]. Knowing this early helps your team consider alternative treatments or early stem cell transplants ^[18][13].

Risk Stratification: The ELN 2022 Categories

Based on your combined results, the European LeukemiaNet (ELN) guidelines group patients into three categories ^[13][4]:

• Favorable: The leukemia has genetic features that make it more likely to go into remission and stay there with chemotherapy alone ^[16].
• Intermediate: The risk of the leukemia returning is moderate; doctors often use a combination of factors to decide if a transplant is needed ^[13].
• Adverse: The leukemia has features that make it harder to treat with standard drugs. These patients are often prioritized for clinical trials or early allogeneic stem cell transplants ^[4][13].

Checklist: Is Your Report Complete?

A complete AML workup should include:

• [ ] Blast Percentage: Is the percentage of immature cells clearly listed? ^[7]
• [ ] Karyotype: Does it list any chromosomal changes (e.g., 46,XY or complex)? ^[5]
• [ ] FISH Panel: Was “fluorescence in situ hybridization” used to quickly check for major translocations? ^[5]
• [ ] Molecular Panel/NGS: Did they test for at least FLT3, NPM1, CEBPA, IDH1/2, and TP53? ^[13][11]
• [ ] Integrated Diagnosis: Is there a final section that summarizes how all these tests fit together? ^[5][3]